Hypersensitivity Clinical Trial
Official title:
Oral Desensitization to Egg With Subsequent Induction of Tolerance for Egg-Allergic Children (CoFAR 3)
The purpose of this study is to determine if oral immunotherapy (OIT) will desensitize a child with an allergy to egg and eventually lead to the development of tolerance to egg.
In the United States, as many as 6% to 8% of children are affected by food allergy. In young
children, allergic reactions to egg can range from mild rash to systemic anaphylaxis. The
usual standard of care for allergy is complete avoidance of this food allergen and treatment
of accidental systemic reactions by access to self-injected epinephrine. However, accidental
exposure to allergens in processed foods may be difficult to avoid. Currently, several
therapeutic strategies are being investigated to prevent and treat food allergies. Since
standard injection (under the skin) immunotherapy for food allergy is associated with a high
rate of allergic reactions, a few studies have recently tried oral immunotherapy (OIT) in
food allergy. The purpose of this study is to determine the safety and efficacy of the
administration of OIT. The intent is to develop desensitization and eventually tolerance to
egg allergen. This study will evaluate tolerance to egg white solid that may be gained by
gradually increasing the amounts of egg white solid given to a child over a long period of
time.
This study will last up to 48 months. The participants will be randomly assigned to receive
oral immunotherapy treatment with egg white solid or placebo. This study will include dose
escalation and maintenance followed by oral food challenge (OFC).
For participants receiving egg OIT, visit 1 consists of multiple small incremental doses of
egg white solid. This is followed by 32-40 weeks of gradual dose escalation to a stable
maintenance dose of egg white solid for at least 8 weeks. At approximately Week 44,
participants are given an OFC using 5 grams of egg white solid to identify desensitized
individuals. Participants and study staff are unblinded following this initial OFC.
Maintenance egg OIT therapy is continued for an additional 1-3 years. Oral Food Challenges
with 10 grams of egg white solid will be performed for participants on maintenance egg OIT at
subsequent time points (approximately Week 96 and annually thereafter) to test for
desensitization. If passed, a repeat OFC after being off therapy for 4-6 weeks will be
performed to test for tolerance. An OFC to test for tolerance will use 10 grams of egg white
solid and be followed by an open feeding of egg.
Participants receiving placebo during dose escalation and maintenance are given an OFC using
5 grams of egg white solid to test for desensitization at approximately 44 weeks. They are
unblinded at that time, continue on an egg-restricted diet, and are followed until up to 2
years. These participants will only receive an OFC at a subsequent time point if their egg
Immunoglobulin E (IgE) declines to be less than 2 kilounits of antibody per liter; this OFC
will use 10 grams of egg white solid and be followed by an open feeding of egg.
At selected visits, blood and urine collection, physical examination, prick skin tests, and
atopic dermatitis and asthma evaluations will occur.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04531540 -
Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
|
Phase 3 | |
Completed |
NCT00988065 -
Sugammadex Hypersensitivity Study (Study P06042)
|
Phase 1 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02588326 -
Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays
|
Phase 1 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT02360072 -
Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
|
||
Completed |
NCT01904604 -
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
|
Phase 2 | |
Completed |
NCT01494649 -
Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity
|
N/A | |
Enrolling by invitation |
NCT05039229 -
Measures for Bioaerosol Reduction in the Salmon Industry
|
N/A | |
Enrolling by invitation |
NCT05675241 -
Characterizing the Inflammation Around Dental Implants
|
||
Completed |
NCT04006106 -
Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
|
||
Completed |
NCT04605471 -
A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
|
||
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Terminated |
NCT05247567 -
Quaternary Ammonium and Immunization in Hairdressers
|
N/A | |
Completed |
NCT05119751 -
Vestibular Versus Sublingual Route of AIT Tablets
|
Phase 4 | |
Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
Active, not recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
Not yet recruiting |
NCT04485299 -
Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient
|
Phase 2/Phase 3 | |
Completed |
NCT02686827 -
DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients.
|
Phase 2 |